RT Journal Article
SR Electronic
A1 Powers, Jenny
T1 Paclitaxel plus Bevacizumab is a Feasible Option for Chemoresistant SCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 9
OP 10
DO 10.1177/155989771403004
UL http://mdc.sagepub.com/content/14/3/9.abstract
AB Salvage treatment combining paclitaxel and bevacizumab was feasible and improved outcomes in heavily pretreated patients with advanced, chemoresistant small cell lung cancer (SCLC) in a small single-center study conducted by the Hellenic Oncology Research Group. Safety concerns were an issue with these patients, who had poor prognoses and few treatment options.